{"id":"biologic-tnfi","safety":{"commonSideEffects":[{"rate":null,"effect":"Infections (including serious infections)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Upper respiratory tract infections"},{"rate":null,"effect":"Tuberculosis reactivation"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TNF inhibitors are biologics that bind to and neutralize TNF-alpha, a key pro-inflammatory cytokine. By blocking TNF signaling, these agents suppress excessive immune activation and inflammation, making them effective in autoimmune and inflammatory diseases. Pfizer's TNFi candidate likely uses a monoclonal antibody or fusion protein approach to achieve TNF inhibition.","oneSentence":"A TNF inhibitor biologic that blocks tumor necrosis factor (TNF) to reduce inflammatory immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:25.210Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Inflammatory bowel disease"},{"name":"Psoriasis"},{"name":"Ankylosing spondylitis"}]},"trialDetails":[{"nctId":"NCT06905288","phase":"","title":"Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-02","conditions":"Ankylosing Spondylitis","enrollment":70},{"nctId":"NCT05782335","phase":"","title":"Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2022-11-01","conditions":"Rheumatoid Arthritis","enrollment":72},{"nctId":"NCT04891640","phase":"NA","title":"Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2021-11-11","conditions":"Juvenile Spondyloarthritis","enrollment":164},{"nctId":"NCT06418529","phase":"","title":"A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-05-15","conditions":"Rheumatoid Arthritis","enrollment":21340},{"nctId":"NCT04692493","phase":"PHASE3","title":"RA-PRO PRAGMATIC TRIAL","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-09-22","conditions":"Rheumatoid Arthritis","enrollment":924},{"nctId":"NCT06469424","phase":"","title":"An Active Surveillance, Post-Authorization Study to Characterize the Safety of Tofacitinib in Patients With Moderately to Severely Active Ulcerative Colitis in the Real-World Setting Using Data From the United Registries for Clinical Assessment and Research (UR-CARE) in the European Union (EU)","status":"RECRUITING","sponsor":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa","startDate":"2024-01-11","conditions":"Ulcerative Colitis","enrollment":104},{"nctId":"NCT05447182","phase":"","title":"People-Powered Medicine (PPM): Rheumatoid Arthritis Non-responders to Biologic Therapies (RANT)","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-06","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT05115903","phase":"PHASE4","title":"Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-12-01","conditions":"Axial Spondyloarthritis","enrollment":15},{"nctId":"NCT04251741","phase":"PHASE4","title":"Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment","status":"UNKNOWN","sponsor":"Reade Rheumatology Research Institute","startDate":"2020-07-31","conditions":"Rheumatoid Arthritis","enrollment":86},{"nctId":"NCT02797769","phase":"","title":"A Time to Cardiovascular Event Analysis Comparing Tocilizumab to Other Biologics in Patients With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-06-02","conditions":"Rheumatoid Arthritis","enrollment":48950},{"nctId":"NCT03331393","phase":"","title":"The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-03-16","conditions":"Rheumatoid Arthritis","enrollment":265},{"nctId":"NCT03419143","phase":"","title":"Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-03-02","conditions":"Psoriatic Arthritis (PsA)","enrollment":190},{"nctId":"NCT05164198","phase":"PHASE4","title":"REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)","status":"UNKNOWN","sponsor":"Hanyang University Seoul Hospital","startDate":"2022-01-15","conditions":"Ankylosing Spondylitis, Axial Spondyloarthritis","enrollment":448},{"nctId":"NCT03011242","phase":"","title":"DC-STAMP: Regulators of Osteoclastogenesis and Response Marker in PsA","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2017-01-11","conditions":"Psoriatic Arthritis","enrollment":47},{"nctId":"NCT02627768","phase":"","title":"A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2015-12-17","conditions":"Psoriatic Arthritis","enrollment":991},{"nctId":"NCT03964649","phase":"","title":"Comparative Analysis of Outcomes Among Patients Treated With Xeljanz vs Biologics","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-01-01","conditions":"Arthritis, Rheumatoid","enrollment":7308},{"nctId":"NCT01557348","phase":"","title":"An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-06","conditions":"Rheumatoid Arthritis","enrollment":1239},{"nctId":"NCT00853385","phase":"PHASE3","title":"A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-05","conditions":"Rheumatoid Arthritis","enrollment":717}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Humira (Adalimumab)"],"phase":"phase_3","status":"active","brandName":"Biologic TNFi","genericName":"Biologic TNFi","companyName":"Pfizer","companyId":"pfizer","modality":"Biologic","firstApprovalDate":"","aiSummary":"A TNF inhibitor biologic that blocks tumor necrosis factor (TNF) to reduce inflammatory immune responses. Used for Rheumatoid arthritis, Inflammatory bowel disease, Psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}